Versanis Bio Announces $70 Million Series A Financing To Advance Bimagrumab For The Treatment Of Obesity
Versanis Bio Announces $70 Million Series A Financing To Advance Bimagrumab For The Treatment Of Obesity
08/31/21, 11:09 AM
Location
oaklandMoney raised
$70 million
Round Type
series a
Versanis Bio today announced the closing of its Series A financing of $70 million to advance the clinical development of bimagrumab, an activin receptor type II antagonist. The company was founded and seeded earlier this year by biotech investment firm Aditum Bio to develop a new therapy for the treatment of metabolic disease and obesity following the in-licensing of bimagrumab from Novartis. Atlas Venture and Medicxi co-led the Series A financing with participation from Aditum Bio, positioning Versanis to initiate an advanced phase 2 program for the treatment of obesity.
Company Info
Location
oakland, california, united states
Additional Info
Versanis Bio was established to develop first-in-class medicines that address medical conditions prevalent in older adults. Bimagrumab is the lead Versanis Bio program, with a goal of helping overweight and obese adults achieve and maintain a healthy body composition. For more information, please visit https://www.versanisbio.com/.